Continuous Manufacturing: The Facts and the Future4 Feb 2019
Gaining momentum in the pharmaceutical industry, continuous manufacturing (CM) presents a new approach to oral solid dosage (OSD) form production and meets the industry’s demands for faster product development, reduced costs, and increased manufacturing flexibility.
Environmentally friendly with a much smaller footprint, CM is helping the pharmaceutical industry to produce higher quality products, enhance drug safety and reduce its industrial footprint, which provides significant advantages.
To examine the fact and fiction of continuous manufacturing in the pharmaceutical industry, GEA, Siemens and Perceptive Engineering will jointly host an inaugural three-day conference comprising two days of presentations from early adopters, a visit to the National Formulation Centre in Sedgefield, UK, courtesy of the Centre for Process Innovation (CPI), and a chance to visit the MSD Cramlington plant (Continuous Direct Compression and Coating).
Taking place on 26–28 March 2019 in Durham, UK, with an expected attendance of 80–120 delegates, the event will focus on the real-life experiences of existing CM users in the development and manufacture of oral solid dosage forms.
Topics on the agenda will include the current status of “going conti” as well as future plans and expectations. Confirmed speakers currently include experts from AstraZeneca, Bayer, CMAC, GSK, Janssen, Merck, RCPE, UCB Pharma and University of Sheffield, to name a few.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation